Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease
The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To evaluate the efficacy and safety of metrifonate, an acetylcholinesterase inhibitor, in patients clinically diagnosed with probable Alzheimer's disease (AD) of mild to moderate severity. METHODS: A prospective, 36-week, multicenter, double-blind, randomized, parallel group study of metrifonate in probable AD patients, including a 2-week screening period, a 26-week double-blind treatment period, and a follow-up visit at 8 weeks post-treatment. A total of 24 ambulatory clinics in the United States in a variety of settings, including contract research organizations, public health facilities, and universities. Patients met diagnostic criteria for probable AD as defined by the work group of the National Institute for Neurological and Communicative Diseases and Stroke and the Alzheimer's Disease and Related Disorders Association. Patients had Mini-Mental State Examination (MMSE) scores of 10 to 26 and Ischemic Scores (Rosen Modification) of <4. A total of 408 patients were enrolled. Percentages of patients completing double-blind treatment were 88% and 79% in the placebo and metrifonate groups, respectively. Rates of discontinuation due to adverse events were 4% in the placebo group and 12% in the metrifonate group. Placebo or metrifonate was administered once daily. Metrifonate-treated patients received a loading dose of 100 to 180 mg based on weight (2.0 mg/kg) for 2 weeks, followed by a maintenance dose of 30 to 60 mg based on weight (0.65 mg/kg) for 24 weeks. Primary efficacy variables were the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) and the Clinician's Interview-Based Impression of Change with Caregiver Input (CIBIC-plus). Secondary efficacy variables included the Neuropsychiatric Inventory (NPI), the Disability Assessment in Dementia, the Global Deterioration Scale (GDS), the ADAS-Noncognitive subscale (ADAS-Noncog), the MMSE, and the Clinician's Interview-Based Impression of Severity with Caregiver Input (CIBIS-plus). Outcome measures reflected changes from baseline at week 26 for all variables. Safety was assessed with incidences of premature termination, treatment-emergent events and mortality, and routine safety evaluations. RESULTS: After 26 weeks of metrifonate therapy, a 2.86-point treatment difference (p = 0.0001) was observed in the ADAS-Cog scores of the intent-to-treat AD patients. The treatment difference in the mean CIBIC-plus score at this time was 0.28 points (p = 0.0071). At week 26, treatment differences also were observed in the mean NPI total score (p = 0.0161). Analysis of the remaining secondary efficacy variables showed treatment differences that favored metrifonate but did not reach statistical significance. Metrifonate adverse events were predominantly mild in intensity. No hepatotoxicity was observed. CONCLUSIONS: Metrifonate was safe and well-tolerated. It enhanced not only the cognitive and global function, but also the behavioral function of patients diagnosed with mild to moderate AD. Therefore, metrifonate appears to be useful in the symptomatic treatment of AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
SELECTIVE LOSS OF CENTRAL CHOLINERGIC NEURONS IN ALZHEIMER'S DISEASE
DAVIES, P. (1976) · The Lancet · doi:10.1016/s0140-6736(76)91936-x · Cited by 3,565
Litvan, I., Agid, Y., Calne, D., Campbell, G., Dubois, B., Duvoisin, R. C., Goetz, C. G., Golbe, L. I., Grafman, J., Growdon, J. H., et al. (1996) · Neurology · doi:10.1212/wnl.47.1.1 · Cited by 2,538
The prevalence of dementia: A quantitative integration of the literature
Jorm, A. F., Korten, A. E., & Henderson, A. S. (1987) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1987.tb02906.x · Cited by 1,296
Pathological verification of ischemic score in differentiation of dementias
Rosen, W. G., Terry, R. D., Fuld, P. A., Katzman, R., & Peck, A. (1980) · Annals of Neurology · doi:10.1002/ana.410070516 · Cited by 1,273
NECROPSY EVIDENCE OF CENTRAL CHOLINERGIC DEFICITS IN SENILE DEMENTIA
Perry, E., Perry, R., Blessed, G., & Tomlinson, B. (1977) · The Lancet · doi:10.1016/s0140-6736(77)91780-9 · Cited by 1,069
Knapp, M. J. (1994) · JAMA · doi:10.1001/jama.271.13.985 · Cited by 1,004
Hayward, R. D., & O'Reilly, G. V. A. (1976) · The Lancet · doi:10.1016/s0140-6736(76)92904-4 · Cited by 647
Evans, D. A., Funkenstein, H. H., Albert, M., Scherr, P. A., Cook, N. R., Chown, M. J., Hebert, L. E., Hennekens, C. H., & Taylor, J. O. (1989) · PubMed · Cited by 599
Treatment of Men with Erectile Dysfunction with Transurethral Alprostadil
Padma-Nathan, H., Hellstrom, W. J. G., Kaiser, F. E., Labasky, R. F., Lue, T. F., Nolten, W. E., Norwood, P. C., Peterson, C. A., Shabsigh, R., Tam, P. Y., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199701023360101 · Cited by 574
Genesis and evolution of behavioral disorders: from infancy to early adult life
(1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.1.1 · Cited by 329
Effect of Tacrine on Behavioral Symptoms in Alzheimer's Disease: An Open-Label Study
Kaufer, D. I., Cummings, J. L., & Christine, D. (1996) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/089198879600900101 · Cited by 206
Metrifonate treatment of the cognitive deficits of Alzheimer's disease
Cummings, J. L., Cyrus, P. A., Bieber, F., Mas, J., Orazem, J., Gulanski, B., & The Metrifonate Study Group* (1998) · Neurology · doi:10.1212/wnl.50.5.1214 · Cited by 172
Self-citationCohler, B. J., ROBBINS, D. M., Hartman, C. R., Shader, R. I., Grunebaum, H. U., Gallant, D. H., & Weiss, J. L. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90017-5 · Cited by 132
Overview: the sex of the therapist
MOGUL, K. M. (1982) · American Journal of Psychiatry · doi:10.1176/ajp.139.1.1 · Cited by 92
Lance, J. W. (1981) · Annals of Neurology · doi:10.1002/ana.410100102 · Cited by 64
Golden Memories, Golden Opportunities
Olson, S. (1998) · Neurology · doi:10.1212/wnl.50.1.1 · Cited by 50
Perkin, R. T. (1995) · Neurology · doi:10.1212/wnl.45.12_suppl_8.s7 · Cited by 36
(1978) · BMJ · doi:10.1136/bmj.2.6129.1 · Cited by 12
Cited by
The cholinergic hypothesis of Alzheimer’s disease: A review of progress
Francis, P. T., Palmer, A. M., Snape, M., & Wilcock, G. K. (1999) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.66.2.137 · Cited by 2,198
Validation of the NPI-Q, a Brief Clinical Form of the Neuropsychiatric Inventory
Kaufer, D., Cummings, J. L., Ketchel, P., Smith, V. M., MacMillan, A., Shelley, T., López, O. L., & DeKosky, S. T. (2000) · Journal of Neuropsychiatry · doi:10.1176/appi.neuropsych.12.2.233 · Cited by 1,973
Doody, R. S., Stevens, J. C., Beck, C., Dubinsky, R. M., Kaye, J. A., Gwyther, L., Mohs, R. C., Thal, L. J., Whitehouse, P. J., DeKosky, S. T., et al. (2001) · Neurology · doi:10.1212/wnl.56.9.1154 · Cited by 1,720
Lyketsos, C. G., Steinberg, M., Tschanz, J. T., Norton, M. C., Steffens, D. C., & Breitner, J. C. S. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.5.708 · Cited by 1,144
A 5-month, randomized, placebo-controlled trial of galantamine in AD
Tariot, P. N., Solomon, P. R., Morris, J. C., Kershaw, P., Lilienfeld, S., Ding, C., & the Galantamine USA- Study Group (2000) · Neurology · doi:10.1212/wnl.54.12.2269 · Cited by 921
Self-citation
Metadata
- Authors
- Morris, J. C., Cyrus, P. A., Orazem, J., Mas, J., Bieber, F., Ruzicka, B. B., & Gulanski, B.
- Venue
- Neurology
- Published
- 1998-05
- Volume
- 50
- Issue
- 5
- Pages
- 1222-1230
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2016659621
- Cited by
- 287
- References
- 18
- FWCI
- 40.97
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.